Online inquiry

IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1567MR)

This product GTTS-WQ1567MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets BMP10&GDF2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_014482.3; NM_016204.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27302; 2658
UniProt ID O95393; Q9UK05
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1567MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14465MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ13244MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ12095MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ5953MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CL-2C
GTTS-WQ15142MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SYNT-001
GTTS-WQ1710MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ11625MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ3829MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW